Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection.
Identifieur interne : 001224 ( PubMed/Corpus ); précédent : 001223; suivant : 001225Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection.
Auteurs : Katherine V. Houser ; Lisa Gretebeck ; Tianlei Ying ; Yanping Wang ; Leatrice Vogel ; Elaine W. Lamirande ; Kevin W. Bock ; Ian N. Moore ; Dimiter S. Dimitrov ; Kanta SubbaraoSource :
- The Journal of infectious diseases [ 1537-6613 ] ; 2016.
English descriptors
- KwdEn :
- Administration, Intranasal, Administration, Intravenous, Animals, Antibodies, Monoclonal, Humanized (therapeutic use), Antibodies, Neutralizing (blood), Antibodies, Neutralizing (therapeutic use), Antibodies, Viral (blood), Antibodies, Viral (therapeutic use), Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Disease Models, Animal, Female, Humans, Immunoglobulins, Intravenous, Lung (virology), Middle East Respiratory Syndrome Coronavirus (genetics), Middle East Respiratory Syndrome Coronavirus (immunology), RNA, Viral (analysis), Rabbits.
- MESH :
- chemical , analysis : RNA, Viral.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Antibodies, Neutralizing, Antibodies, Viral.
- genetics : Middle East Respiratory Syndrome Coronavirus.
- immunology : Coronavirus Infections, Middle East Respiratory Syndrome Coronavirus.
- prevention & control : Coronavirus Infections.
- virology : Lung.
- Administration, Intranasal, Administration, Intravenous, Animals, Disease Models, Animal, Female, Humans, Immunoglobulins, Intravenous, Rabbits.
Abstract
With >1600 documented human infections with Middle East respiratory syndrome coronavirus (MERS-CoV) and a case fatality rate of approximately 36%, medical countermeasures are needed to prevent and limit the disease. We examined the in vivo efficacy of the human monoclonal antibody m336, which has high neutralizing activity against MERS-CoV in vitro. m336 was administered to rabbits intravenously or intranasally before infection with MERS-CoV. Prophylaxis with m336 resulted in a reduction of pulmonary viral RNA titers by 40-9000-fold, compared with an irrelevant control antibody with little to no inflammation or viral antigen detected. This protection in rabbits supports further clinical development of m336.
DOI: 10.1093/infdis/jiw080
PubMed: 26941283
Links to Exploration step
pubmed:26941283Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection.</title><author><name sortKey="Houser, Katherine V" sort="Houser, Katherine V" uniqKey="Houser K" first="Katherine V" last="Houser">Katherine V. Houser</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases.</nlm:affiliation></affiliation></author><author><name sortKey="Gretebeck, Lisa" sort="Gretebeck, Lisa" uniqKey="Gretebeck L" first="Lisa" last="Gretebeck">Lisa Gretebeck</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases.</nlm:affiliation></affiliation></author><author><name sortKey="Ying, Tianlei" sort="Ying, Tianlei" uniqKey="Ying T" first="Tianlei" last="Ying">Tianlei Ying</name><affiliation><nlm:affiliation>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College, Fudan University, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Yanping" sort="Wang, Yanping" uniqKey="Wang Y" first="Yanping" last="Wang">Yanping Wang</name><affiliation><nlm:affiliation>Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland.</nlm:affiliation></affiliation></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases.</nlm:affiliation></affiliation></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases.</nlm:affiliation></affiliation></author><author><name sortKey="Bock, Kevin W" sort="Bock, Kevin W" uniqKey="Bock K" first="Kevin W" last="Bock">Kevin W. Bock</name><affiliation><nlm:affiliation>Comparative Medicine Branch, Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Disease, National Institutes of Health (NIH), Bethesda.</nlm:affiliation></affiliation></author><author><name sortKey="Moore, Ian N" sort="Moore, Ian N" uniqKey="Moore I" first="Ian N" last="Moore">Ian N. Moore</name><affiliation><nlm:affiliation>Comparative Medicine Branch, Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Disease, National Institutes of Health (NIH), Bethesda.</nlm:affiliation></affiliation></author><author><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S" last="Dimitrov">Dimiter S. Dimitrov</name><affiliation><nlm:affiliation>Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland.</nlm:affiliation></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26941283</idno><idno type="pmid">26941283</idno><idno type="doi">10.1093/infdis/jiw080</idno><idno type="wicri:Area/PubMed/Corpus">001224</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001224</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection.</title><author><name sortKey="Houser, Katherine V" sort="Houser, Katherine V" uniqKey="Houser K" first="Katherine V" last="Houser">Katherine V. Houser</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases.</nlm:affiliation></affiliation></author><author><name sortKey="Gretebeck, Lisa" sort="Gretebeck, Lisa" uniqKey="Gretebeck L" first="Lisa" last="Gretebeck">Lisa Gretebeck</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases.</nlm:affiliation></affiliation></author><author><name sortKey="Ying, Tianlei" sort="Ying, Tianlei" uniqKey="Ying T" first="Tianlei" last="Ying">Tianlei Ying</name><affiliation><nlm:affiliation>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College, Fudan University, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Yanping" sort="Wang, Yanping" uniqKey="Wang Y" first="Yanping" last="Wang">Yanping Wang</name><affiliation><nlm:affiliation>Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland.</nlm:affiliation></affiliation></author><author><name sortKey="Vogel, Leatrice" sort="Vogel, Leatrice" uniqKey="Vogel L" first="Leatrice" last="Vogel">Leatrice Vogel</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases.</nlm:affiliation></affiliation></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases.</nlm:affiliation></affiliation></author><author><name sortKey="Bock, Kevin W" sort="Bock, Kevin W" uniqKey="Bock K" first="Kevin W" last="Bock">Kevin W. Bock</name><affiliation><nlm:affiliation>Comparative Medicine Branch, Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Disease, National Institutes of Health (NIH), Bethesda.</nlm:affiliation></affiliation></author><author><name sortKey="Moore, Ian N" sort="Moore, Ian N" uniqKey="Moore I" first="Ian N" last="Moore">Ian N. Moore</name><affiliation><nlm:affiliation>Comparative Medicine Branch, Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Disease, National Institutes of Health (NIH), Bethesda.</nlm:affiliation></affiliation></author><author><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S" last="Dimitrov">Dimiter S. Dimitrov</name><affiliation><nlm:affiliation>Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland.</nlm:affiliation></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The Journal of infectious diseases</title><idno type="eISSN">1537-6613</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Administration, Intravenous</term><term>Animals</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antibodies, Neutralizing (blood)</term><term>Antibodies, Neutralizing (therapeutic use)</term><term>Antibodies, Viral (blood)</term><term>Antibodies, Viral (therapeutic use)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (prevention & control)</term><term>Disease Models, Animal</term><term>Female</term><term>Humans</term><term>Immunoglobulins, Intravenous</term><term>Lung (virology)</term><term>Middle East Respiratory Syndrome Coronavirus (genetics)</term><term>Middle East Respiratory Syndrome Coronavirus (immunology)</term><term>RNA, Viral (analysis)</term><term>Rabbits</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Administration, Intravenous</term><term>Animals</term><term>Disease Models, Animal</term><term>Female</term><term>Humans</term><term>Immunoglobulins, Intravenous</term><term>Rabbits</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">With >1600 documented human infections with Middle East respiratory syndrome coronavirus (MERS-CoV) and a case fatality rate of approximately 36%, medical countermeasures are needed to prevent and limit the disease. We examined the in vivo efficacy of the human monoclonal antibody m336, which has high neutralizing activity against MERS-CoV in vitro. m336 was administered to rabbits intravenously or intranasally before infection with MERS-CoV. Prophylaxis with m336 resulted in a reduction of pulmonary viral RNA titers by 40-9000-fold, compared with an irrelevant control antibody with little to no inflammation or viral antigen detected. This protection in rabbits supports further clinical development of m336. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26941283</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>213</Volume><Issue>10</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection.</ArticleTitle><Pagination><MedlinePgn>1557-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiw080</ELocationID><Abstract><AbstractText>With >1600 documented human infections with Middle East respiratory syndrome coronavirus (MERS-CoV) and a case fatality rate of approximately 36%, medical countermeasures are needed to prevent and limit the disease. We examined the in vivo efficacy of the human monoclonal antibody m336, which has high neutralizing activity against MERS-CoV in vitro. m336 was administered to rabbits intravenously or intranasally before infection with MERS-CoV. Prophylaxis with m336 resulted in a reduction of pulmonary viral RNA titers by 40-9000-fold, compared with an irrelevant control antibody with little to no inflammation or viral antigen detected. This protection in rabbits supports further clinical development of m336. </AbstractText><CopyrightInformation>Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Houser</LastName><ForeName>Katherine V</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gretebeck</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ying</LastName><ForeName>Tianlei</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College, Fudan University, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Leatrice</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamirande</LastName><ForeName>Elaine W</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bock</LastName><ForeName>Kevin W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Comparative Medicine Branch, Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Disease, National Institutes of Health (NIH), Bethesda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Ian N</ForeName><Initials>IN</Initials><AffiliationInfo><Affiliation>Comparative Medicine Branch, Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Disease, National Institutes of Health (NIH), Bethesda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimitrov</LastName><ForeName>Dimiter S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subbarao</LastName><ForeName>Kanta</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MERS-CoV</Keyword><Keyword MajorTopicYN="N">human mAb</Keyword><Keyword MajorTopicYN="N">m336</Keyword><Keyword MajorTopicYN="N">prophylaxis</Keyword><Keyword MajorTopicYN="N">rabbits</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>02</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26941283</ArticleId><ArticleId IdType="pii">jiw080</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiw080</ArticleId><ArticleId IdType="pmc">PMC4837915</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12123-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17620608</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2007 Dec;25(12):1421-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18066039</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Aug 1;369(5):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23782161</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2013 Sep;13(9):752-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23891402</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2014 Jan;52(1):67-75</Citation><ArticleIdList><ArticleId IdType="pubmed">24153118</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2014 Jul;88(14):7796-805</Citation><ArticleIdList><ArticleId IdType="pubmed">24789777</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2014 Nov 1;59(9):1225-33</Citation><ArticleIdList><ArticleId IdType="pubmed">24829216</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2014 Dec;29:301-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25303830</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2015 Jun;89(11):6131-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25810539</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2015 Jul;59(7):4162-72</Citation><ArticleIdList><ArticleId IdType="pubmed">25941218</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43</Citation><ArticleIdList><ArticleId IdType="pubmed">26124093</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2015 Oct;122:28-38</Citation><ArticleIdList><ArticleId IdType="pubmed">26192750</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Public Health. 2017 Mar - Apr;10(2):191-194</Citation><ArticleIdList><ArticleId IdType="pubmed">27140697</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001224 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001224 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26941283
|texte= Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26941283" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |